Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma

View through CrossRef
Abstract Abstract 4718 Improved experimental therapies are needed for Multiple Myeloma (MM). Despite major progress in treatment and initial induction of remission, myeloma remains an incurable disease. Although immunotherapy and, in particular, the employment of NK cells offers an approach of interest for the treatment of Multiple Myeloma (MM), recent studies have shown that myeloma cells utilise a number different mechanisms to impair NK and T cell functions. Important amongst these mechanisms is the reduced expression of CD80 in the sub-populations of PBMC isolated from myeloma patients. We have previously demonstrated CD80/IL-2 mediated stimulation of NK and T cells isolated from AML patients (as measured by proliferation, cytokine release and target cell specific cytolytic activity). In the present study we have examined the ability of genetically modified MM cells engineered to express CD80 and IL-2 to stimulate NK cell functions. These studies confirm the ability of MM cells to suppress NK cell functions in healthy PBMC and show that in contrast to the unmodified MM cells, the CD80/IL-2 expressing MM cells are able to stimulate a moderate increase in NK and T cell numbers and a significant increase in the fraction of NK cells with activatory receptors (NKp44, NKp30, NKp46) and activation markers (CD69) on the cell surface of both NK and T cells. More importantly for potential therapeutic applications the stimulated NK cells show increased cytolytic activity against the unmodified MM cells. This data suggest that CD80/IL-2 MM cells may be able to overcome the immune suppressive functions of unmodified MM cells and to stimulate NK, and T cell mediated responses against the unmodified MM cells. Therefore CD80/IL-2 expressing MM cells may provide a suitable cellular vaccine for NK cell stimulation and possibly the induction of broader ranging immunological responses against multiple myeloma cells. Disclosures: No relevant conflicts of interest to declare.
Title: CD80-IL2 Expressing Myeloma Cells for Immune Gene Therapy of Multiple Myeloma
Description:
Abstract Abstract 4718 Improved experimental therapies are needed for Multiple Myeloma (MM).
Despite major progress in treatment and initial induction of remission, myeloma remains an incurable disease.
Although immunotherapy and, in particular, the employment of NK cells offers an approach of interest for the treatment of Multiple Myeloma (MM), recent studies have shown that myeloma cells utilise a number different mechanisms to impair NK and T cell functions.
Important amongst these mechanisms is the reduced expression of CD80 in the sub-populations of PBMC isolated from myeloma patients.
We have previously demonstrated CD80/IL-2 mediated stimulation of NK and T cells isolated from AML patients (as measured by proliferation, cytokine release and target cell specific cytolytic activity).
In the present study we have examined the ability of genetically modified MM cells engineered to express CD80 and IL-2 to stimulate NK cell functions.
These studies confirm the ability of MM cells to suppress NK cell functions in healthy PBMC and show that in contrast to the unmodified MM cells, the CD80/IL-2 expressing MM cells are able to stimulate a moderate increase in NK and T cell numbers and a significant increase in the fraction of NK cells with activatory receptors (NKp44, NKp30, NKp46) and activation markers (CD69) on the cell surface of both NK and T cells.
More importantly for potential therapeutic applications the stimulated NK cells show increased cytolytic activity against the unmodified MM cells.
This data suggest that CD80/IL-2 MM cells may be able to overcome the immune suppressive functions of unmodified MM cells and to stimulate NK, and T cell mediated responses against the unmodified MM cells.
Therefore CD80/IL-2 expressing MM cells may provide a suitable cellular vaccine for NK cell stimulation and possibly the induction of broader ranging immunological responses against multiple myeloma cells.
Disclosures: No relevant conflicts of interest to declare.

Related Results

Trogocytosis in Multiple Myeloma.
Trogocytosis in Multiple Myeloma.
Abstract Trogocytosis is the transfer of cell membrane material from one cell to another during short term cell-cell contact. Recent studies have suggested that the ...
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
Abstract Multiple myeloma (MM) is a malignancy of terminally differentiated clonal plasma cells displaying significant molecular heterogeneity with 7 subgroups defin...
Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia
Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia
Abstract Objective To detect the percentage of CD5+ B cells in peripheral blood (PB) of patients with autoimmune hemolytic anemia (AIHA) /Evans syndrome and the expr...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Low Dose of Interleukin-2 Therapy Could Prevent Chronic Graft-Versus-Host Disease: A Randomized Study
Low Dose of Interleukin-2 Therapy Could Prevent Chronic Graft-Versus-Host Disease: A Randomized Study
Abstract Acknowledgments: This study was supported by the grants from the National Natural Science Foundation of China (Grant No. 81270644 and 81230013), the Major S...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus
Introduction: Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma with a case prevalence in Prof. Dr. I.G.N.G. Ngoerah Hospital for the...

Back to Top